2021年最新SCI期刊影响因子查询系统
NUCLEAR MEDICINE AND BIOLOGY 期刊详细信息
基本信息
期刊名称 | NUCLEAR MEDICINE AND BIOLOGY NUCLEAR MEDICINE AND BIOLOGY |
---|---|
期刊ISSN | 0969-8051 |
期刊官方网站 | http://www.journals.elsevier.com/nuclear-medicine-and-biology/ |
是否OA | 否 |
出版商 | Elsevier Inc. |
出版周期 | Bimonthly |
始发年份 | 1993 |
年文章数 | 75 |
最新影响因子 | 2.947(2021) |
中科院SCI期刊分区
大类学科 | 小类学科 | Top | 综述 |
---|---|---|---|
医学3区 | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING 核医学3区 | 否 | 否 |
CiteScore
CiteScore排名 | CiteScore | SJR | SNIP | ||
---|---|---|---|---|---|
学科 | 排名 | 百分位 | 2.23 | 0.674 | 0.809 |
Medicine Radiology Nuclear Medicine and imaging |
70 / 272 | 74% |
|||
Biochemistry, Genetics and Molecular Biology Molecular Medicine |
98 / 165 | 40% |
|||
Biochemistry, Genetics and Molecular Biology Cancer Research |
122 / 191 | 36% |
补充信息
自引率 | 6.20% |
---|---|
H-index | 82 |
SCI收录状况 |
Science Citation Index
Science Citation Index Expanded |
官方审稿时间 | |
网友分享审稿时间 | 数据统计中,敬请期待。 |
PubMed Central (PML) | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0969-8051%5BISSN%5D |
投稿指南
期刊投稿网址 | http://ees.elsevier.com/nucmedbio/default.asp?pg=preRegistration.asp |
---|---|
收稿范围 | Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis, in vitro and ex vivo studies, in vivobiodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration. If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized. These multidisciplinary studies should validate the mechanism of localization whether the probe is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the probe to changes in disease or treatment, although studies validating mechanism alone are acceptable. Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field. Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed. |
收录体裁 | |
投稿指南 | https://www.elsevier.com/journals/nuclear-medicine-and-biology/0969-8051/guide-for-authors |
投稿模板 | |
参考文献格式 | https://www.elsevier.com/journals/nuclear-medicine-and-biology/0969-8051/guide-for-authors |
编辑信息 |